[Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine].
A
A
Yachachi Monfort
F
F
Cortés Pastor
A
A
de la Rubia Nieto
M J
MJ
Sánchez Garre
D015761:4-Aminopyridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000077770:Amifampridine; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015624:Lambert-Eaton Myasthenic Syndrome / Q000188:drug therapy*; D026902:Potassium Channel Blockers / Q000627:therapeutic use*; D011729:Pyridostigmine Bromide / Q000627:therapeutic use*
D002800:Cholinesterase Inhibitors; D026902:Potassium Channel Blockers; D015761:4-Aminopyridine; D011729:Pyridostigmine Bromide; D000077770:Amifampridine